This company is innovating where it matters most, which could prove highly lucrative down the road.Cancer diagnostic specialist Exact Sciences (EXAS -0.04%) has lagged the market over the past three years. The pandemic and the economic troubles that followed disrupted the company's operations, and the healthcare leader remains unprofitable. However, one famous name on Wall Street continues to have faith in Exact Sciences.That person is Cathie Wood, CEO of Ark Invest, an investment management firm that still ...

Exact Sciences Corporation (EXAS) recently reported a promising outcome for the non-endoscopic Oncoguard Esophagus test, developed in collaboration with the Mayo Clinic Comprehensive Cancer Center. The test, currently in development for the detection of esophageal adenocarcinoma (EAC) and its precursors, including Barrett’s esophagus (BE), has demonstrated high sensitivity and specificity.The findings from the test’s algorithm training and testing were recently published in the Clinical Gastroenterology and ...

A month has gone by since the last earnings report for Exact Sciences (EXAS) . Shares have added about 4.2% in that time frame, outperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Exact Sciences due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts. Exact Sciences Q4 Loss Narrows, Revenues Rise ...

Exact Sciences Corporation (EXAS) recently announced the online publication of the BLUE-C study results in The New England Journal of Medicine (NEJM). The 20,000-participant, multi-center and prospective study was designed to determine the performance characteristics of the company’s next-generation Cologuard Plus multitarget stool DNA test.The publication of the "Next-Generation Multitarget Stool DNA Test for Colorectal Cancer (CRC) Screening" peer-reviewed study in NEJM reflects a decade of Exact Sciences ...

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced online publication of the BLUE-C study results in The New England Journal of Medicine. The peer-reviewed study, " Next-Generation Multitarget Stool DNA Test for Colorectal Cancer Screening", will also appear in the journal's March 14, 2024 print issue. The 20,000-participant BLUE-C study was designed to determine the performance characteristics of Exact Sciences’ ...

Exact Sciences (EXAS) closed the last trading session at $61.46, gaining 0.8% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $95.53 indicates a 55.4% upside potential.The mean estimate comprises 17 short-term price targets with a standard deviation of $15.39. While the lowest estimate of $73 indicates an 18.8% increase from the current price level, the most optimistic analyst expe ...

Underdogs stocks carry almost universal appeal. It’s one thing to go with the rest of the crowd. It’s quite another to take your time to find some diamonds in the rough that could yield considerable returns.Basically, these hidden gems represent the universal desire to pioneer a particular accomplishment. For example, we all remember who first stepped foot on the moon. We don’t really discuss who was the last person to do it, as monumental of a triumph that it is.Now, that’s not to say that you can’t extrac ...

Key PointsNancy Pelosi bought Palo Alto Networks before and after the 27% stock price implosion. Victoria Spartz is buying into Simon Property Group's long-term appeal. Kevin Hearn is an active investor; he bought JPM and sold these two stocks analysts are bullish on. 5 stocks we like better than Palo Alto NetworksThe STOCK Act of 2012 was supposed to halt insider trading by members of Congress, but let’s be honest. The STOCK Act can’t really stop Congresspeople from trading on insider knowledge; they’re in ...

Company Participation in Conferences - Exact Sciences Corp management will participate in the TD Cowen 44th Annual Health Care Conference in Boston with a fireside chat scheduled for Monday March 4 2024 at 1:30 pm ET [1] - Investors can access the webcast of the conference in the investor relations section of Exact Sciences website [1] Company Overview - Exact Sciences Corp is a leading provider of cancer screening and diagnostic tests offering clarity to patients and healthcare professionals for early life-changing actions [2] - The company has achieved success with its Cologuard® and Oncotype® tests and is investing in its pipeline to develop innovative solutions for use before during and after a cancer diagnosis [2]

Exact Sciences Corporation (EXAS) reported a net loss of 27 cents per share for fourth-quarter 2023, a significant improvement from the year-ago loss of 72 cents per share as well as the Zacks Consensus Estimate of a loss of 53 cents.Full-year net loss was $1.13 per share, narrower than the Zacks Consensus Estimate of a loss of $1.39. It also marked an improvement from a loss of $3.54 per share loss incurred in 2022.Revenues in DetailFourth-quarter consolidated revenues were $646.9 million, up 17% (up 18% o ...